Microenvironment‐induced TIMP2 loss by cancer‐secreted exosomal miR‐4443 promotes liver metastasis of breast cancer
Jinyan Wang(Shanghai Academy of Agricultural Sciences), Jifeng Feng(Nanjing Medical University), Hanzi Xu(Jiangsu Cancer Hospital), Su‐Jin Yang(Jiangsu Cancer Hospital), Heda Zhang(Jiangsu Province Hospital), Qian Zhang(Jiangsu Province Hospital), Dandan Wang(Jiangsu Province Hospital), Siying Zhou(Nanjing University of Chinese Medicine), Shanliang Zhong(Jiangsu Cancer Hospital)
Cited by 69
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner
|International Journal of Nanomedicine|2017|241